Celgene Corp.

CELG NAS
Pharmaceuticals
Summit, NJ
2016 Revenue (US$ Millions)$11,229
Revenue Growth (%)21.32%
2015 Revenue (US$ Millions)$9,256
Net Income (US$ Millions)$1,999
Common Shares Outstanding (Millions)778.6
Earnings Per Share (US$)$2.49
Price to Earnings Ratio48.31
Total Equity (US$ Millions)$6,599
Return on Equity (%)33.78%
Long Term Debt (US$ Millions)$13,789
Debt to Equity Ratio (%)2.09%
Market Capitalization (US$ Millions)$90,123
Total Assets (US$ Millions)$28,086
Current Assets (US$ Millions)$10,868
Inventories (US$ Millions)$498
Current Liabilities (US$ Millions)$2,959
Cost Of Goods Sold (US$ Millions)$438
Asset Turnover0.41
Inventory Turnover0.93